Tolman Wiker
Pac Premier
Farmers merchants
Nixon Peabody
Express Pros
You are here:  Home  >  Biotech  >  Current Article

Our view: Setbacks are costly but biotech industry copes

By and   /   Friday, July 19th, 2019  /   Comments Off on Our view: Setbacks are costly but biotech industry copes

    Print       Email
Amid a boom in the biotech industry in the Conejo Valley, comes a reminder that drug discovery is expensive and not risk-free. On July 11, Thousand Oaks-based Amgen and partners Novartis, another pharmaceuticals giant, and the Banner Alzheimer’s Institute abruptly halted clinical trials for CNP520, a drug that had shown promise for the prevention of…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

MindBody invests in healthy living platform Fitt

Read More →